Newron Pharmaceuticals SpA
SIX:NWRN

Watchlist Manager
Newron Pharmaceuticals SpA Logo
Newron Pharmaceuticals SpA
SIX:NWRN
Watchlist
Price: 20.7 CHF 7.14%
Market Cap: 413.2m CHF

Operating Margin
Newron Pharmaceuticals SpA

50.9%
Current
-148%
Average
6.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
50.9%
=
Operating Profit
26.2m
/
Revenue
51.4m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
IT
Newron Pharmaceuticals SpA
SIX:NWRN
413.1m CHF
51%
US
Eli Lilly and Co
NYSE:LLY
954.7B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
505.3B USD
27%
CH
Roche Holding AG
SIX:ROG
252.4B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
209.5B GBP
24%
CH
Novartis AG
SIX:NOVN
203.3B CHF
33%
US
Merck & Co Inc
NYSE:MRK
246.3B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
206B USD
11%
US
Pfizer Inc
NYSE:PFE
146.7B USD
29%
No Stocks Found

Newron Pharmaceuticals SpA
Glance View

Market Cap
413.1m CHF
Industry
Pharmaceuticals

Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 25 full-time employees. The company went IPO on 2006-12-12. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.

NWRN Intrinsic Value
10.39 CHF
Overvaluation 50%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
50.9%
=
Operating Profit
26.2m
/
Revenue
51.4m
What is the Operating Margin of Newron Pharmaceuticals SpA?

Based on Newron Pharmaceuticals SpA's most recent financial statements, the company has Operating Margin of 50.9%.

Back to Top